Cogent Biosciences/COGT

$7.30

2.53%
-
1D1W1MYTD1YMAX

About Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Ticker

COGT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Robbins

Employees

164

Headquarters

Waltham, United States

COGT Metrics

BasicAdvanced
$641.57M
Market cap
-
P/E ratio
-$2.40
EPS
1.56
Beta
-
Dividend rate
$641.57M
1.55812
$13.50
$3.67
2.13M
7.094
-62.65%
-99.26%
-70.07%
2.922
2.489
1.92%

What the Analysts think about COGT

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
128.77% upside
High $26.00
Low $8.00
$7.30
Current price
$16.70
Average price target

COGT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-54.3M
-1.81%
Profit margin
0%
-

COGT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.83%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.54
-$0.59
-$0.64
-$0.63
-
Expected
-$0.57
-$0.54
-$0.50
-$0.56
-$0.52
Surprise
-5.43%
8.3%
27.8%
11.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cogent Biosciences stock?

Cogent Biosciences (COGT) has a market cap of $641.57M as of April 24, 2024.

What is the P/E ratio for Cogent Biosciences stock?

The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of April 24, 2024.

Does Cogent Biosciences stock pay dividends?

No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Cogent Biosciences dividend payment date?

Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.

What is the beta indicator for Cogent Biosciences?

Cogent Biosciences (COGT) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cogent Biosciences stock price target?

The target price for Cogent Biosciences (COGT) stock is $16.7, which is 139.94% above the current price of $6.96. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cogent Biosciences stock

Buy or sell Cogent Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing